Holen Sie sich die Stockscreener-App
53.92
0.76%
-0.355
Schlusskurs vom Vortag:
$54.28
Offen:
$54.48
24-Stunden-Volumen:
2.91M
Relative Volume:
0.57
Marktkapitalisierung:
$108.01B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$8.29B
KGV:
14.72
EPS:
3.6638
Netto-Cashflow:
$5.71B
1W Leistung:
-1.17%
1M Leistung:
-8.59%
6M Leistung:
+31.94%
1J Leistung:
+37.32%
1-Tages-Spanne:
$53.67
$54.73
1-Wochen-Bereich:
$53.67
$56.05
52-Wochen-Spanne:
$32.38
$61.70
Gsk Plc Adr Stock (GSK) Company Profile
Compare GSK vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
53.92 | 108.73B | 43.11B | 8.29B | 5.71B | 3.6638 |
|
LLY
Lilly Eli Co
|
989.36 | 872.68B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.42 | 583.29B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
222.85 | 398.49B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
190.52 | 298.53B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.07 | 294.33B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-06 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
FDA Broadens Access To GSK's Respiratory Syncytial Virus Shot For Younger High-Risk Adults - Benzinga
GSK Out-Licenses Rights for Rare Liver Disease Drug to Alfasigma - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Quantbot Technologies LP - MarketBeat
Price Over Earnings Overview: GSK - Sahm
GlaxoSmithKline Pharma: Can India’s GSK Arm Still Reward US Investors? - AD HOC NEWS
GSK PLC Sponsored ADR $GSK Shares Sold by Kahn Brothers Group Inc. - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Short Interest Down 26.3% in February - MarketBeat
CapEx per share of GSK PLC ADR Cert.Deposito Arg.Repr. 0.25 ADRs – BCBA:GSKD - TradingView
Fisher Asset Management LLC Purchases 889,210 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Antibiotics Market - GlobeNewswire Inc.
GSK Stock Price, Quote & Chart | GSK PLC-SPON ADR (NYSE:GSK) - ChartMill
GSK Expands Pipeline With $950 Million Pulmonary Hypertension Power Play - Sahm
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus - Finviz
GSK (GSK) Announces 75.6% Vaccine Effectiveness for Arexvy in Real-World RSV Study - Finviz
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
GlaxoSmithKline Pharma: Quiet India Move, Big Signal for U.S. Portfolios? - AD HOC NEWS
GSK plc (GSK) Q4 Results Topped Forecasts as Specialty Medicines Jump 17% - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of "Reduce" from Brokerages - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Consensus Rating of “Reduce” from Brokerages - Defense World
Is GSK PLC Gaining or Losing Market Support? - Sahm
BI Asset Management Fondsmaeglerselskab A S Reduces Stake in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Gets EU Approval for Expanded Use of Nucala in COPD - Finviz
GSK PLC Sponsored ADR (NYSE:GSK) Declares Dividend Increase$0.49 Per Share - MarketBeat
ANALYSIS-Novo Nordisk risks weight-loss price war as discount pressures deepen - Sahm
3 International Stocks to Buy for 2026 - Morningstar
GSK Set up for Steady Long-Term Growth as Portfolio and Pipeline Develop - Morningstar
GSK's Q4 Earnings & Sales Beat Estimates, Stock Up on '26 Outlook - TradingView
10 best global blue-chip stocks to buy for the long term - Morningstar Australia
GSK plc (ADR): Quiet Rally, Loud Expectations – Is the Stock Finally Escaping Its Legal Overhang? - AD HOC NEWS
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth - Finviz
10 Best Blue-Chip Stocks to Buy for the Long Term - Morningstar
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Oncolytic Virotherapy Market - GlobeNewswire Inc.
GSK to Boost Respiratory & Immunology Pipeline With $2.2B RAPT Buyout - Finviz
GSK plc (ADR): Defensive pharma heavyweight tests investors’ patience as Wall Street edges cautiou - AD HOC NEWS
GSK To Acquire RAPT Therapeutics In $2.2 Billion Bet On Food Allergy Breakthrough - Sahm
Jakub Rochlitz @TheDividendFund: "𝗜𝘀 𝘁𝗵𝗲 "𝗔𝗜-𝗮𝘁-𝗮𝗻𝘆-𝗰𝗼𝘀𝘁" 𝗲𝗿𝗮 𝗰𝗼𝗼𝗹𝗶𝗻𝗴..." - eToro
GSK PLC Sponsored ADR (NYSE:GSK) Sees Significant Growth in Short Interest - MarketBeat
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.23%
2.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):